Neurogene (NGNE) Revenue (2018 - 2024)
Neurogene posted quarterly Revenue of $925000.0 for Q2 2024, down 99.91% on a QoQ basis from $1.0 billion in Q3 2019.
Neurogene (NGNE) has 3 years of Revenue data on file, last reported at $925000.0 in Q2 2024.
- For the quarter ending Q2 2024, Revenue changed N/A year-over-year to $925000.0; the trailing twelve-month figure through Jun 2025 stood at $925000.0 (changed 0.0% YoY), and the FY2024 full-year result was $925000.0, changed N/A from the prior year.
- Revenue for Q2 2024 stood at $925000.0, down from $1.0 billion in the prior quarter.
- Across five years, Revenue topped out at $925000.0 in Q2 2024 and bottomed at $925000.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 925,000.00 |
| Sep 30, 2019 | 1.00 Bn |
| Jun 30, 2018 | 25.00 Mn |